A multicenter, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma

被引：0

作者：

Quach, Hang ^{[1
]}

Parmar, Gurdeep ^{[2
]}

Ocio, Enrique M. ^{[3
]}

Prince, H. Miles ^{[4
,5
]}

Oriol, Albert ^{[6
,7
]}

Crowther, Helen ^{[8
]}

Tsukada, Nobuhiro ^{[9
]}

Bories, Pierre ^{[10
]}

Madan, Sumit ^{[11
]}

Nathwani, Nitya ^{[12
]}

Sunami, Kazutaka ^{[13
]}

Semiond, Dorothee ^{[14
]}

Yu, Disa ^{[14
]}

Cordero, Paul ^{[15
]}

Mace, Sandrine ^{[16
]}

Suzan, Florence ^{[16
]}

Moreau, Philippe ^{[17
]}

机构：

[1] Univ Melbourne, St Vincents Hosp, Clin Hematol Serv, Melbourne, Australia

[2] Illawarra Canc Care Ctr, Wollongong, Australia

[3] Univ Cantabria, Hosp Univ Marques Valdecilla IDIVAL, Santander, Spain

[4] Epworth HealthCare, Mol Oncol & Canc Immunol, Melbourne, Australia

[5] Univ Melbourne, Melbourne, Australia

[6] Hosp Germans Trias i Pujol, Inst Catala Oncol, Barcelona, Spain

[7] Hosp Germans Trias i Pujol, Inst Josep Carreras, Barcelona, Spain

[8] Blacktown & Mt Druitt Hosp, Dept Paediat, Blacktown, NSW, Australia

[9] Japanese Red Cross Med Ctr, Dept Hematol, Tokyo, Japan

[10] Inst Univ Canc Toulouse, Inst Claudius Regaud, Inst Claudius Regaud, Toulouse, France

[11] Banner MD Anderson Canc Ctr, Gilbert, AZ USA

[12] City Hope Natl Med Ctr, Dept Hematol, Duarte, CA USA

[13] Natl Hosp Org Okayama Med Ctr, Dept Hematol, Okayama, Japan

[14] Sanofi, Res & Dev, Cambridge, MA USA

[15] Sanofi, Res & Dev, Reading, England

[16] Sanofi, Res & Dev, Vitry Sur Seine, France

[17] Univ Hosp Nantes, Dept Hematol, Nantes, France

来源：

HAEMATOLOGICA | 2024年 / 109卷 / 12期

关键词：

OPEN-LABEL;

D O I：

10.3324/haematol.2023.284730

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：4078 / 4082

页数：5

共 50 条

[21] Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma
Costa, Luciano J.
Davies, Faith E.
Monohan, Gregory P.
Kovacsovics, Tibor
Burwick, Nicholas
Jakubowiak, Andrzej
Kaufman, Jonathan L.
Hong, Wan-Jen
Dail, Monique
Salem, Ahmed Hamed
Yang, Xiaoqing
Masud, Abdullah A.
Munasinghe, Wijith
Ross, Jeremy A.
Bueno, Orlando F.
Kumar, Shaji K.
Stadtmauer, Edward A.
BLOOD ADVANCES, 2021, 5 (19) : 3748 - 3759
[22] Belantamab in Combination with Dexamethasone in Patients with Triple-class Relapsed/Refractory Multiple Myeloma
Atieh, Tahani
Atrash, Shebli
Ahmed, Nausheen
Mohan, Meera
Cui, Wei
Shune, Leyla
Hajjar, Susana
Mahmoudjafari, Zahra
Quick, Julie
Wishna, Anne
Riffel, Justin
McGuirk, Joseph
Mohyuddin, Ghulam Rehman
Abdallah, Al-Ola
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (12): : 912 - 919
[23] Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma
Mu, Song
Kuroda, Yoshiaki
Shibayama, Hirohiko
Hino, Masayuki
Tajima, Takeshi
Corrado, Claudia
Lin, Rong
Waldron, Edward
Binlich, Florence
Suzuki, Kenshi
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 72 (02) : 153 - 161
[24] Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial
Fu, Wei-Jun
Wang, Ya-Fei
Zhao, Hong-Guo
Niu, Ting
Fang, Bai-Jun
Liao, Ai-Jun
Bai, Hai
Lu, Jin
BMC CANCER, 2022, 22 (01)
[25] Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
Gasparetto, Cristina
Lentzsch, Suzanne
Schiller, Gary
Callander, Natalie
Tuchman, Sascha
Chen, Christine
White, Darrell
Kotb, Rami
Sutherland, Heather
Sebag, Michael
Baljevic, Muhamed
Bensinger, William
Leblanc, Richard
Venner, Chris
Bahlis, Nizar
Rossi, Adriana
Biran, Noa
Sheehan, Heidi
Saint-Martin, Jean-Richard
Van Domelen, Dane
Kai, Kazuharu
Shah, Jatin
Shacham, Sharon
Kauffman, Michael
Lipe, Brea
EJHAEM, 2021, 2 (01): : 56 - 65
[26] Adverse Hematological and Non-Hematological Events in Patients With Relapsed/Refractory Multiple Myeloma That Are Responsive to Daratumumab, Pomalidomide and Dexamethasone
Alkharabsheh, Omar
Bellman, Polina
Mahmoudjafari, Zahra
Cui, Wei
Atrash, Shebli
Paul, Barry
Hashmi, Hamza
Shune, Leyla
Ahmed, Nausheen
Abdallah, Al-Ola
JOURNAL OF HEMATOLOGY, 2023, 12 (01) : 1 - 6
[27] Carfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factors
Dimopoulos, M. A.
Sonneveld, P.
Siegel, D.
Palumbo, A.
San-Miguel, J.
ANNALS OF ONCOLOGY, 2015, 26 (11) : 2247 - 2256
[28] Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial
Trudel, Suzanne
Mccurdy, Arleigh
Louzada, Martha L.
Parkin, Stephen
White, Darrell
Chu, Michael P.
Kotb, Rami
Mian, Hira
Othman, Ibraheem
Su, Jiandong
Khan, Aniba
Gul, Engin
Reece, Donna
NATURE MEDICINE, 2024, 30 (02) : 543 - 551
[29] Real-world evidence of efficacy and safety of pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: Czech registry data
Sandecka, Viera
Pour, Ludek
Spicka, Ivan
Minarik, Jiri
Radocha, Jakub
Jelinek, Tomas
Pavlicek, Petr
Jungova, Alexandra
Kessler, Petr
Wrobel, Marek
Stork, Martin
Straub, Jan
Pika, Tomas
Capkova, Lenka
Sevcikova, Sabina
Maisnar, Vladimir
Hajek, Roman
NEOPLASMA, 2022, 69 (06) : 1474 - 1479
[30] Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma
Tun, Han W.
Johnston, Patrick B.
DeAngelis, Lisa M.
Atherton, Pamela J.
Pederson, Levi D.
Koenig, Patricia A.
Reeder, Craig B.
Omuro, Antonio M. Padula
Schiff, David
O'Neill, Brian
Pulido, Jose
Jaeckle, Kurt A.
Grommes, Christian
Witzig, Thomas E.
BLOOD, 2018, 132 (21) : 2240 - 2248

← 1 2 3 4 5 →